Director:
Richard Pazdur, M.D.
Special Assistant:
Dianne Spillman
The Oncology
Program works with Centers within FDA and with
external stakeholders to initiate, develop,
co-ordinate, and communicate cross-cutting FDA
initiatives in oncology. The Program's
strategic goals are to identify emerging
technologies that may speed the development of
new therapies for cancer; examine the
regulatory implications of such breakthroughs;
and devise strategies for consistent, rational
alignment of regulatory policy with scientific
advances.
Major areas of
focus in the program include:
Back to Top
Office of Oncology Drug
Products